Botulinum toxin A treatment in toddlers with cerebral palsy

Acta Paediatr. 2010 Aug;99(8):1156-62. doi: 10.1111/j.1651-2227.2010.01767.x. Epub 2010 Mar 11.

Abstract

Aims: In this study the aim was to evaluate the effect of botulinum toxin A (BoNT-A) treatment on muscle tone, contracture development and gait pattern in young children with cerebral palsy (CP).

Method: Fifteen children with spastic CP (mean age = 16 months) were included in a randomized control study. All received a daily stretching programme and children in the BoNT-A group additionally received two injections, 6 months apart in the gastrocnemius muscle. Outcomes were assessed at baseline, and after 1 and 3.5 years. A 3D gait-analysis was performed at 5 years of age.

Results: Plantarflexor muscle tone in the BoNT-A group was significantly reduced after 3.5 years, while the muscle tone at the ankle and knee in the control group remained unchanged. The change-score in knee-flexion muscle tone between the groups was significantly different after 3.5 years. The knee joint ROM was significantly increased at 1 year in the BoNT-A group but reduced at the knee and ankle joints in the control group after 3.5 years. No group differences were found for gait analysis, GMFM-66 or PEDI.

Conclusion: Early treatment of BoNT-A in children with spastic CP may decrease muscle tone and decelerate contracture development after 3.5 years. The effect on gait development remains inconclusive.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / drug therapy*
  • Child, Preschool
  • Contracture / etiology
  • Female
  • Follow-Up Studies
  • Gait / drug effects
  • Humans
  • Infant
  • Injections, Intramuscular
  • Male
  • Muscle Hypotonia / etiology
  • Muscle Spasticity / drug therapy
  • Muscle Tonus / drug effects
  • Neuromuscular Agents / adverse effects
  • Neuromuscular Agents / therapeutic use*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A